Skip to main content
Top
Published in: Breast Cancer Research 6/2011

Open Access 01-12-2011 | Research article

Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer

Authors: Richa Tiwary, Weiping Yu, Linda A deGraffenried, Bob G Sanders, Kimberly Kline

Published in: Breast Cancer Research | Issue 6/2011

Login to get access

Abstract

Introduction

Adjuvant treatment with tamoxifen substantially improves survival of women with estrogen-receptor positive (ER+) tumors. Tamoxifen resistance (TAMR) limits clinical benefit. RRR-α-tocopherol ether-linked acetic acid analogue (α-TEA) is a small bioactive lipid with potent anticancer activity. We evaluated the ability of α-TEA in the presence of tamoxifen to circumvent TAMR in human breast cancer cell lines.

Methods

Two genotypically matched sets of TAM-sensitive (TAMS) and TAM-resistant (TAMR) human breast cancer cell lines were assessed for signal-transduction events with Western blotting, apoptosis induction with Annexin V-FITC/PI assays, and characterization of cholesterol-rich microdomains with fluorescence staining. Critical involvement of selected mediators was determined by using RNA interference and chemical inhibitors.

Results

Growth-factor receptors (total and phosphorylated forms of HER-1 and HER-2), their downstream prosurvival mediators pAkt, pmTOR, and pERK1/2, phosphorylated form of estrogen receptor-α (pER-α at Ser-167 and Ser-118, and cholesterol-rich lipid microdomains were highly amplified in TAMR cell lines and enhanced by treatment with TAM. α-TEA disrupted cholesterol-rich microdomains, acted cooperatively with TAM to reduce prosurvival mediators, and induced DR5-mediated mitochondria-dependent apoptosis via an endoplasmic reticulum stress-triggered pro-death pJNK/CHOP/DR5 amplification loop. Furthermore, methyl-β-cyclodextrin (MβCD), a chemical disruptor of cholesterol rich microdomains, acted cooperatively with TAM to reduce prosurvival mediators and to induce apoptosis.

Conclusions

Data for the first time document that targeting cholesterol-rich lipid microdomains is a potential strategy to circumvent TAMR, and the combination of α-TEA + TAM can circumvent TAMR by suppression of prosurvival signaling via disruption of cholesterol-rich lipid microdomains and activation of apoptotic pathways via induction of endoplasmic reticulum stress.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed
2.
go back to reference Fabian CJ: The what and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Clin Practice. 2007, 12: 2051-2063. Fabian CJ: The what and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Clin Practice. 2007, 12: 2051-2063.
3.
go back to reference Lewis JS, Jordan VC: Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005, 591: 247-263. 10.1016/j.mrfmmm.2005.02.028.CrossRefPubMed Lewis JS, Jordan VC: Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005, 591: 247-263. 10.1016/j.mrfmmm.2005.02.028.CrossRefPubMed
4.
go back to reference Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.CrossRefPubMed Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.CrossRefPubMed
5.
go back to reference Hurvitz SA, Pietras RJ: Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008, 113: 2385-2397. 10.1002/cncr.23875.CrossRefPubMed Hurvitz SA, Pietras RJ: Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008, 113: 2385-2397. 10.1002/cncr.23875.CrossRefPubMed
6.
go back to reference Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003, 22: 7316-7339. 10.1038/sj.onc.1206937.CrossRefPubMed Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003, 22: 7316-7339. 10.1038/sj.onc.1206937.CrossRefPubMed
7.
go back to reference Arpino G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008, 29: 217-233.CrossRefPubMedPubMedCentral Arpino G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008, 29: 217-233.CrossRefPubMedPubMedCentral
8.
go back to reference Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004, 96: 926-935. 10.1093/jnci/djh166.CrossRefPubMed Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004, 96: 926-935. 10.1093/jnci/djh166.CrossRefPubMed
9.
go back to reference Li YC, Park MJ, Ye SY, Kim CW, Kim YN: Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006, 168: 1107-1118. 10.2353/ajpath.2006.050959.CrossRefPubMedPubMedCentral Li YC, Park MJ, Ye SY, Kim CW, Kim YN: Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006, 168: 1107-1118. 10.2353/ajpath.2006.050959.CrossRefPubMedPubMedCentral
10.
go back to reference Patra SK: Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 2008, 1785: 182-206.PubMed Patra SK: Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 2008, 1785: 182-206.PubMed
11.
go back to reference Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-Ud-Din: Signaling through sphingolipid microdomains of the plasma membrane: the concept of signaling platform. Glycoconj J. 2000, 17: 191-197. 10.1023/A:1026585006064.CrossRefPubMed Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-Ud-Din: Signaling through sphingolipid microdomains of the plasma membrane: the concept of signaling platform. Glycoconj J. 2000, 17: 191-197. 10.1023/A:1026585006064.CrossRefPubMed
12.
go back to reference Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, Kline K: Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med. 2009, 234: 1244-1252. 10.3181/0901-RM-8.CrossRef Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, Kline K: Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med. 2009, 234: 1244-1252. 10.3181/0901-RM-8.CrossRef
13.
go back to reference Jia L, Yu W, Wang P, Sanders BG, Kline K: In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells. Prostate. 2008, 68: 849-860. 10.1002/pros.20750.CrossRefPubMed Jia L, Yu W, Wang P, Sanders BG, Kline K: In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells. Prostate. 2008, 68: 849-860. 10.1002/pros.20750.CrossRefPubMed
14.
go back to reference Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K: Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer. 2004, 48: 95-105. 10.1207/s15327914nc4801_13.CrossRefPubMed Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K: Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer. 2004, 48: 95-105. 10.1207/s15327914nc4801_13.CrossRefPubMed
15.
go back to reference Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K: Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med. 2004, 229: 1169-1176. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K: Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med. 2004, 229: 1169-1176.
16.
go back to reference Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K: Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther. 2003, 2: 437-444.PubMed Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K: Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther. 2003, 2: 437-444.PubMed
17.
go back to reference Hahn T, Fried K, Hurley LH, Akporiaye ET: Orally active α-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol Cancer Ther. 2009, 8: 1570-1578. 10.1158/1535-7163.MCT-08-1079.CrossRefPubMedPubMedCentral Hahn T, Fried K, Hurley LH, Akporiaye ET: Orally active α-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol Cancer Ther. 2009, 8: 1570-1578. 10.1158/1535-7163.MCT-08-1079.CrossRefPubMedPubMedCentral
18.
go back to reference Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K: Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010, 5: e11865-10.1371/journal.pone.0011865.CrossRefPubMedPubMedCentral Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K: Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010, 5: e11865-10.1371/journal.pone.0011865.CrossRefPubMedPubMedCentral
19.
go back to reference Shun MC, Yu W, Park SK, Sanders BG, Kline K: Downregulation of epidermal growth factor receptor expression contributes to alpha-TEA's proapoptotic effects in human ovarian cancer cell lines. J Oncol. 2010, 2010: 824571-CrossRefPubMedPubMedCentral Shun MC, Yu W, Park SK, Sanders BG, Kline K: Downregulation of epidermal growth factor receptor expression contributes to alpha-TEA's proapoptotic effects in human ovarian cancer cell lines. J Oncol. 2010, 2010: 824571-CrossRefPubMedPubMedCentral
20.
go back to reference Tiwary R, Yu W, Sanders BG, Kline K: α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br J Cancer. 2011, 104: 101-109. 10.1038/sj.bjc.6606019.CrossRefPubMed Tiwary R, Yu W, Sanders BG, Kline K: α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br J Cancer. 2011, 104: 101-109. 10.1038/sj.bjc.6606019.CrossRefPubMed
21.
go back to reference Yu W, Tiwary R, Li J, Park SK, Jia L, Xiong A, Simmons-Menchaca M, Sanders BG, Kline K: α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. Mol Carcinog. 2010, 49: 964-973. 10.1002/mc.20681.CrossRefPubMed Yu W, Tiwary R, Li J, Park SK, Jia L, Xiong A, Simmons-Menchaca M, Sanders BG, Kline K: α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. Mol Carcinog. 2010, 49: 964-973. 10.1002/mc.20681.CrossRefPubMed
22.
go back to reference Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K: Critical roles for JNK, c-Jun, and Fas/FasL-signaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Prostate. 2008, 68: 427-441. 10.1002/pros.20716.CrossRefPubMed Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K: Critical roles for JNK, c-Jun, and Fas/FasL-signaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Prostate. 2008, 68: 427-441. 10.1002/pros.20716.CrossRefPubMed
23.
go back to reference Wang P, Yu W, Hu Z, Jia L, Iyer VR, Sanders BG, Kline K: Involvement of JNK/p73/NOXA in vitamin E analog-induced apoptosis of human breast cancer cells. Mol Carcinog. 2008, 47: 436-445. 10.1002/mc.20400.CrossRefPubMed Wang P, Yu W, Hu Z, Jia L, Iyer VR, Sanders BG, Kline K: Involvement of JNK/p73/NOXA in vitamin E analog-induced apoptosis of human breast cancer cells. Mol Carcinog. 2008, 47: 436-445. 10.1002/mc.20400.CrossRefPubMed
24.
25.
go back to reference Hahn T, Jagadish B, Mash EA, Garrison K, Akporiaye ET: α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. Breast Cancer Res. 2011, 13: R4-10.1186/bcr2808.CrossRefPubMedPubMedCentral Hahn T, Jagadish B, Mash EA, Garrison K, Akporiaye ET: α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. Breast Cancer Res. 2011, 13: R4-10.1186/bcr2808.CrossRefPubMedPubMedCentral
26.
go back to reference Jayo A, Conde I, Lastres P, Martínez C, Rivera J, Vicente V, González-Manchón C: L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica. 2010, 95: 1158-1166. 10.3324/haematol.2009.018572.CrossRefPubMedPubMedCentral Jayo A, Conde I, Lastres P, Martínez C, Rivera J, Vicente V, González-Manchón C: L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica. 2010, 95: 1158-1166. 10.3324/haematol.2009.018572.CrossRefPubMedPubMedCentral
27.
go back to reference Beknke O, Tranum-Jensen J, van Deurs B: Filipin as a cholesterol probe. I. Morphology of filipin-cholesterol interaction in lipid model systems. Eur J Cell Biol. 1984, 35: 189-199.PubMed Beknke O, Tranum-Jensen J, van Deurs B: Filipin as a cholesterol probe. I. Morphology of filipin-cholesterol interaction in lipid model systems. Eur J Cell Biol. 1984, 35: 189-199.PubMed
28.
go back to reference Chou T-C: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70: 440-446. 10.1158/0008-5472.CAN-09-1947.CrossRefPubMed Chou T-C: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70: 440-446. 10.1158/0008-5472.CAN-09-1947.CrossRefPubMed
29.
go back to reference Pike LJ: Lipid rafts: bringing order to chaos. J Lipid Res. 2003, 44: 655-667. 10.1194/jlr.R200021-JLR200.CrossRefPubMed Pike LJ: Lipid rafts: bringing order to chaos. J Lipid Res. 2003, 44: 655-667. 10.1194/jlr.R200021-JLR200.CrossRefPubMed
30.
go back to reference Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer Suppl. 2006, 1: S15-S24.CrossRef Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer Suppl. 2006, 1: S15-S24.CrossRef
31.
go back to reference Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010, 126: 545-562. 10.1002/ijc.24750.CrossRefPubMed Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010, 126: 545-562. 10.1002/ijc.24750.CrossRefPubMed
32.
go back to reference deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res. 2004, 10: 8059-8067. 10.1158/1078-0432.CCR-04-0035.CrossRefPubMed deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res. 2004, 10: 8059-8067. 10.1158/1078-0432.CCR-04-0035.CrossRefPubMed
33.
go back to reference Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR: Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res. 2010, 16: 1486-1497. 10.1158/1078-0432.CCR-09-1764.CrossRefPubMed Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR: Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res. 2010, 16: 1486-1497. 10.1158/1078-0432.CCR-09-1764.CrossRefPubMed
34.
go back to reference Chu I, Blackwell K, Chen S, Slingerland J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005, 65: 18-25.PubMed Chu I, Blackwell K, Chen S, Slingerland J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005, 65: 18-25.PubMed
35.
go back to reference Nahta R, Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232: 123-138. 10.1016/j.canlet.2005.01.041.CrossRefPubMed Nahta R, Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232: 123-138. 10.1016/j.canlet.2005.01.041.CrossRefPubMed
36.
go back to reference Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands. Int J Mol Med. 2007, 20: 3-10.PubMed Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands. Int J Mol Med. 2007, 20: 3-10.PubMed
37.
go back to reference Pike LJ: Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta. 2005, 1746: 260-273. 10.1016/j.bbamcr.2005.05.005.CrossRefPubMed Pike LJ: Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta. 2005, 1746: 260-273. 10.1016/j.bbamcr.2005.05.005.CrossRefPubMed
38.
go back to reference Márquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ: Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006, 246: 91-100. 10.1016/j.mce.2005.11.020.CrossRefPubMed Márquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ: Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006, 246: 91-100. 10.1016/j.mce.2005.11.020.CrossRefPubMed
39.
go back to reference Freeman MR, Cinar B, Lu ML: Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab. 2005, 16: 273-279. 10.1016/j.tem.2005.06.002.CrossRefPubMed Freeman MR, Cinar B, Lu ML: Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab. 2005, 16: 273-279. 10.1016/j.tem.2005.06.002.CrossRefPubMed
40.
go back to reference Li J, Yu W, Tiwary R, Park SK, Xiong A, Sanders BG, Kline K: α-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes. Cancer Cell Int. 2010, 10: 40-10.1186/1475-2867-10-40.CrossRefPubMedPubMedCentral Li J, Yu W, Tiwary R, Park SK, Xiong A, Sanders BG, Kline K: α-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes. Cancer Cell Int. 2010, 10: 40-10.1186/1475-2867-10-40.CrossRefPubMedPubMedCentral
41.
go back to reference Yu C, Alterman M, Dobrowsky RT: Ceramide displaces cholesterol from lipid rafts and decreases the association of the cholesterol binding protein caveolin-1. J Lipid Res. 2005, 46: 1678-1691. 10.1194/jlr.M500060-JLR200.CrossRefPubMed Yu C, Alterman M, Dobrowsky RT: Ceramide displaces cholesterol from lipid rafts and decreases the association of the cholesterol binding protein caveolin-1. J Lipid Res. 2005, 46: 1678-1691. 10.1194/jlr.M500060-JLR200.CrossRefPubMed
42.
go back to reference Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K: Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue, alpha-TEA. Cancer Res. 2004, 64: 4263-4269. 10.1158/0008-5472.CAN-03-2327.CrossRefPubMed Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K: Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue, alpha-TEA. Cancer Res. 2004, 64: 4263-4269. 10.1158/0008-5472.CAN-03-2327.CrossRefPubMed
Metadata
Title
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
Authors
Richa Tiwary
Weiping Yu
Linda A deGraffenried
Bob G Sanders
Kimberly Kline
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3063

Other articles of this Issue 6/2011

Breast Cancer Research 6/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine